Regeneron Pharmaceuticals Inc
(MEX:REGN)
MXN
18667
16.7 (0.09%)
Market Cap: 2.04 Tn
Enterprise Value: 1.90 Tn
PE Ratio: 24.59
PB Ratio: 3.63
GF Score: 92/100 Regeneron Pharmaceuticals Inc at Credit Suisse Healthcare Conference - Scottsdale Transcript
Nov 12, 2019 / 03:00PM GMT
Release Date Price:
MXN6730.34
(+3.29%)
Evan David Seigerman;dit Suisse AG
CrÃ;Research Division - VP & Senior Equity Research Analyst
© -
Good morning. My name is Evan Seigerman, I'm the Senior Large-Cap Biotechnology Analyst here at Crédit Suisse, and welcome to the First Day of the 2019 Global Healthcare Conference in Scottsdale. To kick off the conference, we have Regeneron Pharmaceuticals and from Regeneron, we have Dr. Len Schleifer, the Founder and CEO; and Bob Landry, CFO. Bob?
Robert E. Landry;Evan David Seigerman;dit Suisse AG
Regeneron Pharmaceuticals, Inc. - Executive VP of Finance & CFO;CrÃ;Research Division - VP & Senior Equity
Sure. So I know we're being webcast. So good morning and good afternoon to everybody. Len and I will be making forward-looking statements at this event. And again, it contains risks and uncertainties, and I encourage everyone to go to our recently filed third quarter 10-Q or our 10-K, which outlines the risk factors associated with Regeneron Pharmaceuticals.
- ©
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot